Protalix signals $100M+ Elfabrio royalties by 2030 as Phase II PRX-115 trial advances
Source: SeekingAlpha
2025-08-14 12:48:40 ET
More on Protalix BioTherapeutics
- Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript
- Protalix BioTherapeutics appoints Gilad Mamlok as CFO
- Seeking Alpha’s Quant Rating on Protalix BioTherapeutics
- Historical earnings data for Protalix BioTherapeutics
- Financial information for Protalix BioTherapeutics
Read the full article on Seeking Alpha
For further details see:
Protalix signals $100M+ Elfabrio royalties by 2030 as Phase II PRX-115 trial advances
Protalix BioTherapeutics Inc.
NASDAQ: PLX
PLX Trading
0.89% G/L:
$2.825 Last:
353,729 Volume:
$2.82 Open:
PLX Latest News
March 11, 2026 06:50:00 am
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026
March 09, 2026 06:00:00 am
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa)
PLX Stock Data
$215,126,659
70,448,955
0.23%
25
N/A
Biotechnology & Life Sciences
Healthcare
US
Hackensack
